"
Team:UC Davis/Project
From 2009.igem.org
What is Celiac Disease?
Celiac Disease is an autoimmune
disorder that occurs inside the small
intestine. When the body cannot digest gliadin (a component of gluten)
properly,
this leads to an immune response in the surface of the small intestine
(14).
Furthermore, different people have different reactions to this immune
response
such as bloating, diarrhea, and weight loss (14). It has been estimated
that
about one out of 133 Americans are currently suffering from this
disease (11);
including one of our teammate's friends, and that was what sparked our
interest
in designing this project.
What happens in the normal small
intestine?
In the normal small intestine,
the brush border membrane on the surface
digests starches and other sugars, proteins, and fat droplets and lets
their
breakdown products pass into the bloodstream.
The brush border membrane in
the small intestine of people suffering from
Celiac Disease allows large molecules such as gliadin to go straight
into the
blood stream without directing them through the transcellular route.
Once
gliadin passes through, Antigen Presenting Cells (APCs) recognize
gliadin as a
foreign object and will attack. This immune response results in
inflammation of
the surface of the intestine with loss of the normal cells required for
absorption of sugars, protein, and fat from the diet.
The immune response not only causes abdominal pain, bloating,
diarrhea and
weight loss it may also damage intestinal villi, which are important
for
absorbing nutrients. The destruction of villi eventually leads to a
lack of
absorption of different nutrients, which can lead to malnutrition (14).
Some
people affected with this disorder can also suffer from autoimmune
thyroid
disease, autoimmune liver disease, and rheumatoid arthritis (diseases
in
which body immune system attacks healthy cells/tissues) (14).
Current
treatments:
Currently, no cure has been found
for this illness. The only way to avoid
some of celiac disease’s symptoms is by adopting a gluten free diet
(14, 12,
and 11). However, you are more likely to find gluten in your everyday
diet, and
people with celiac disease must purchase gluten-free substances from
specialized grocery stores. "Oral supplementation with prolyl
oligopeptidases that can digest and detoxify gluten has therefore been
proposed
as a potential therapeutic approach."(8). However, enzymes studied
earlier
were not able to degrade gluten inside stomach (before it reaches small
intestine) because they were "irreversibly inactivated by pepsin and
acidic pH, both present in the stomach."(8)
Nevertheless, over the past
years, researchers have discovered an enzyme
from Aspergillus niger, a newly identified prolyl endoprotease,
that was
observed to "work optimally at 4-5pH and remains stable at 2pH"(8)
and maybe this enzyme will lead us to an alternative treatment for this
disorder (8). Studies have shown that prolyl-endoprotease from Aspergillus
niger is able to "degrade gluten in vitro and under conditions
similar
to the ones present in the gastrointestinal tract." (8) ; but due
to
licensing restrictions we have opted not to work with this protein.
Recently (year 2007), a study
has suggested an alternative approach by
combining a glutamine-specific endoprotease (EP-B2 from barley) and a
prolyl
endopeptidase (SC PEP from Sphingomonas
capsulata); with gastric
activity and
complementary substrate specificity there is a possibility of
increasing the
safe threshold of ingested gluten (12). One of the advantages of this
“combination product is that both enzymes are active and stable in
stomach and
can therefore be administered as lyophilized powders or simple capsules
or
tablets” (12).
Our approach:
Gliadin induces an immune
system response when it is absorbed into
the blood stream through the small intestine. We plan to take advantage
of this by breaking down gliadin in the stomach before it reaches the
small intestine. We have developed a secretion system to release an
enzyme that can break down gliadin. Also, in order to prevent our
delivery system from taking residence anywhere outside of the stomach,
we plan to incorporate the difference in pH between the stomach and
small intestine with a pH-inducible apoptosis system. By adopting these
two systems, we will create a pH-moderated secretion system.
Unlike other suggested treatments
requiring the consumption of capsules or tablets, our method of using E.
coli as our delivery system is more cost- and time-efficient.
Our project is
split into two parts:
1.Induced Secretion
- Adding secretion
- Gene sequence for secretion system
- Assay for measuring protein localization and activity
